



NeuroScientific
BIOPHARMACEUTICALS

Level 1, 45 Stirling Highway
Nedlands WA 6009 Australia
www.neuroscientific.com

COMPANY SECRETARY RESIGNATION AND APPOINTMENT

Perth, Australia; 20 April 2020: NeuroScientific Biopharmaceuticals Ltd (ASX:NSB, “NSB” or the “Company”), would like to advise the appointment of Abby Macnish as Company Secretary, and responsible for all Company Secretary responsibilities for NSB, following a period of concurrent management and handover with former Company Secretary Thomas Spencer, and effective today 20 April 2020. Abby holds degrees in Commerce and Science, is a CFA charterholder and has over 15 years’ experience in investments and equity markets.

Former co-Company Secretary Thomas Spencer has resigned, effective today, 20 April 2020. NSB’s CEO & Managing Director, Matt Liddelow, stated, “Thomas has been an integral part of NSB through our ASX listing process to the present, and we wish him every success in his new endeavors.”

Brian Leedman, Chairman of NSB said, “We welcome Abby to NSB and look forward to utilising her skills and experience as we proceed with our development of EmtinB as a novel treatment for neurodegenerative diseases including Alzheimers, MS and Glaucoma.”

This announcement has been authorised for release by Matthew Liddelow.

End

About NeuroScientific Biopharmaceuticals Ltd

NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. The Company’s product portfolio includes EmtinB, a novel therapeutic peptide most advanced as a treatment for Alzheimer’s disease; and other related peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Chairman
bl@neuroscientific.com
+61 412 281 780